I think IMM will have better results with eftilagimod and Keytruda in all cancers than Relatlimab and Nivolumab.
Unfortunately we will have to wait and see if BMS can provdie data in other cancer for comparison.
FDA is likely aware of this.
If so FDA will provide IMM information on the FDA needs to complete for eftilagimod approval later this month.
Overnight Market report, page-88
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
0.003(0.78%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $397.4K | 1.227M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 415403 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 150624 | 31 |
View Market Depth
| Last trade - 13.04pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |